Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models
- 1 April 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (7) , 2168-2177
- https://doi.org/10.1158/1078-0432.ccr-06-0918
Abstract
Purpose: The use of genetically engineered mouse (GEM) models for preclinical testing of anticancer therapies is hampered by variable tumor latency, incomplete penetrance, and complicated breeding schemes. Here, we describe and validate a transplantation strategy that circumvents some of these difficulties.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- BRCA1 dysfunction in sporadic basal-like breast cancerOncogene, 2006
- Clonogenic assay with established human tumour xenograftsEuropean Journal Of Cancer, 2004
- Integrating pharmacology and in vivo cancer models in preclinical and clinical drug developmentEuropean Journal Of Cancer, 2004
- “Of mice and men”European Journal Of Cancer, 2004
- Orthotopic models of cancer for preclinical drug evaluationEuropean Journal Of Cancer, 2004
- 17beta-Estradiol Is a Hormonal Regulator of Mirex Tumor Promotion Sensitivity in MiceToxicological Sciences, 2002
- Chemotherapeutic Profiles of Human Tumors Implanted in SCID Mice Showing Appreciable Inconsistencies with Those in Nude Mice.Experimental Animals, 1997
- Activated neu Induces Rapid Tumor ProgressionJournal of Biological Chemistry, 1996
- In vivo cultivation of tumor cells in hollow fibersLife Sciences, 1995
- Cytotoxic Cs in Immunodeficient Athymic MiceImmunopharmacology and Immunotoxicology, 1994